A number of other research firms have also recently issued reports on HROW. Zacks Investment Research raised Harrow Health from a sell rating to a buy rating and set a $6.00 price objective for the company in a research report on Friday, March 15th. TheStreet raised Harrow Health from a d- rating to a c rating in a research report on Wednesday, May 1st.
Shares of NASDAQ HROW opened at $7.72 on Monday. The company’s 50 day moving average is $6.03. Harrow Health has a 52 week low of $1.99 and a 52 week high of $8.05. The company has a quick ratio of 3.22, a current ratio of 3.43 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $187.01 million, a PE ratio of 12.66 and a beta of -0.28.
Harrow Health (NASDAQ:HROW) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.14). Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The business had revenue of $12.29 million during the quarter, compared to analyst estimates of $12.10 million. As a group, sell-side analysts forecast that Harrow Health will post -0.1 earnings per share for the current fiscal year.
In other news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.57, for a total value of $45,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 30,000 shares of company stock valued at $151,200. Insiders own 12.43% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Birchview Capital LP acquired a new stake in Harrow Health in the first quarter valued at approximately $896,000. FineMark National Bank & Trust acquired a new stake in Harrow Health in the first quarter valued at approximately $113,000. Acadian Asset Management LLC acquired a new stake in Harrow Health in the first quarter valued at approximately $1,983,000. Alambic Investment Management L.P. acquired a new stake in Harrow Health in the first quarter valued at approximately $252,000. Finally, EAM Global Investors LLC acquired a new stake in Harrow Health in the first quarter valued at approximately $171,000. 32.14% of the stock is owned by institutional investors.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Read More: Trade War
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.